Theremia

Startup

Theremia is an AI-powered solution transforming precision medicine in neurology and psychiatry, with a first focus on Parkinson’s, Alzheimer’s, multisclerosis and depression. By integrating real-world data (RWD) and clinical trial data (RCT) with molecular and pharmacological insights, Theremia identifies the most responsive patient subpopulations and optimizes treatment adjustments to maximize efficacy and minimize side effects.
This personalized approach rectifies the inefficiencies of the "one-size-fits-all" model, leading to more effective treatments, better patient adherence, and extended drug lifecycles for biotechs and pharmaceutical companies.
Backed by €3 million from Eurazeo and Salica Invests and incubated at Agoranov, our team of 10 experts collaborates with over 20 leading medical institutions in France, the UK, and the US, conducting multiple proof-of-concept studies (POCs) in neurodegenerative and psychiatric disorders.

website